Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies

Biological Psychiatry

Volumn 53, Issue 2, 2003, Pages 112-120

  Michelson, David ^a,b   Adler, Lenard ^c   Spencer, Thomas ^d   Reimherr, Frederick W ^e   West, Scott A ^f   Allen, Albert J ^a   Kelsey, Douglas ^a   Wernicke, Joachim ^a   Dietrich, Anthony ^g   Milton, Denái ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f Psychiatric Institute of Florida   (United States)

^g Neuropsychiatric Associates   (United States)

Author keywords

ADHD; Adults; Atomoxetine; Nonstimulant

Indexed keywords

ATOMOXETINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FEMALE; HUMAN; HYPERACTIVITY; HYPERHIDROSIS; IMPULSIVENESS; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MODEL; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; VERTIGO; XEROSTOMIA;

EID: 12244298956     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01671-2     Document Type: Article

References (42)

1. Diagnostic and statistical manual of mental disorders DSM-IV-TR . 2000;American Psychiatric Press, Washington, DC.
2. Bech P., Cialdella P., Haugh M.C., Birkett M.A., Hours A., Boissel J.P., et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry. 176:2000;421-428.
3. Biederman J., Baldessarini R.J., Wright V., Knee D., Harmatz J.S. A double-blind placebo controlled study of desipramine in the treatment of ADD I. Efficacy . J Am Acad Child Adolesc Psychiatry. 28:1989;777-784.
4. Biederman J., Mick E., Faraone S.V. Age-dependent decline of symptoms of attention deficit hyperactivity disorder Impact of remission definition and symptom type . Am J Psychiatry. 157:2000;816-818.
5. Biederman J., Spencer T.J. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 46:1999;1234-1242.
6. Biederman J., Wilens T., Mick E., Spencer T., Faraone S.V. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 104:1999;e20.
7. Brown R.T., Borden K.A. Hyperactivity at adolescence Some misconceptions and new directions . J Clin Child Psychol. 15:1986;194-209.
8. Bymaster FP, Katner J, Nelson DL, Hemricke-Luecke SK, Threlkeld PG, Heiligenstein JH, et al (2002): Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit hyperactivity disorder. Neuropsychopharmacology 27:699-711.
9. Conners C.K., Casat C.D., Gualtieri C.T., Weller E., Reader M., Reiss A., et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 35:1996;1314-1321.
10. Conners C.K., Erhardt D., Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). 1999;Multi-Health Systems, North Tonawanda, NY.
11. DeVeaugh-Geiss J, Biederman J, Conners CK, Swanson J, Dietrich A, Greenhill LL, et al (2001): GW320659 in the treatment of adult attention-deficit/hyperactivity disorder. NCDEU 41st Annual Meeting Poster Presentations/Abstract Booklet.
12. Devoto P., Flore G., Pani L., Gessa G.L. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry. 6:2001;657-664.
13. First M.B., Spitzer G.M., Spitzer R.L., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version. 2000;Biometrics Research, New York State Psychiatric Institute, New York.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976;United States Department of Health, Education, and Welfare, Bethesda, MD.
15. Hamilton M.A. A rating scale of depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
16. Hechtman L. Attention-deficit hyperactivity disorder. Hechtman L. Do They Grow Out of It? Long-term Outcomes of Childhood Disorders. 1996;17-38 American Psychiatric Press, Washington, DC.
17. Heil S.H., Holmes H.W., Bickel W.K., Higgins S.T., Badger G.J., Laws H.F., et al. Comparison of the subject-rated, physiological and psychomotor effects of atomoxetine and methylphenidate in recreational drug users. Drug Alcohol Depend. 67:2002;149-156.
18. Heiligenstein J, Spencer T, Faries DE, Biederman J, Kratochvil CJ, Conners CK (2000): Efficacy of atomoxetine vs. placebo in pediatric outpatients with ADHD. Proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 24-29, New York, NY.
19. Hudziak J. The identification of phenotypes for molecular genetic studies of common childhood psychopathology. Blum K., Noble E. Handbook of Psychiatric Genetics. 1997;CRC Press, New York.
20. Klein R.G., Mannuzza S. The long-term outcome of the attention-deficit disorder/hyperkinetic syndrome. Sagvolden T., Archer T. Attention Deficit Disorder Clinical and Basic Research . 1989;71-91 Lawrence Erlbaum Associates, Hillsdale, NJ.
21. Klein R.G., Mannuzza S. Long-term outcome of hyperactive children A review . J Am Acad Child Adolesc Psychiatry. 30:1991;383-387.
22. Kratochvil C.J., Heiligenstein J.H., Dittman R., Spencer T., Biederman J., Wernicke J.F., et al. Atomoxetine and methylphenidate treatment in children with ADHD A prospective, randomized, open-label trial . J Am Acad Child Adolesc Psychiatry. 41:2002;776-784.
23. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C (2002): Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901.
24. Michelson D., Faries D.E., Wernicke J., Kelsey D.K., Kendrick K.L., Sallee F.R., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder A randomized, placebo-controlled, dose-response study . Pediatrics. 108:2001;e83.
25. Murphy K., Barkley R.A. Attention deficit hyperactivity disorder adults Comorbidities and adaptive impairments . Compr Psychiatry. 37:1996;393-401.
26. Popper C.W. Pharmacological alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 9:2000;605-646.
27. Safer D.J. Commentary - stimulant treatment in the community. J Am Acad Child Adolesc Psychiatry. 39:2000;989-992.
28. SAS/STAT Software: Changes and enhancements through release 6.12. 1997;SAS Institute, Cary, NC.
29. Seidman L.J., Biederman J., Weber W., Hatch M., Faraone S.V. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry. 44:1998;260-268.
30. Spencer T., Wilens T., Biederman J., Faraone S.V., Ablon J.S., Lapey K.A. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention deficit hyperactivity. Arch Gen Psychiatry. 52:1995;434-443.
31. Spencer T.J., Biederman J., Wilens T.E., Prince J., Hatch M., Jones J., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 155:1998;693-695.
32. Thorley G. Review of follow-up and follow-back studies of childhood hyperactivity. Psychol Bull. 96:1984;116-132.
33. Versiani M., Amin M., Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol. 20:2000;28-34.
34. Weiss G. Follow up studies on outcome of hyperactive children. Psychopharmacol Bull. 21:1985;169-177.
35. Weiss G. Research issues in longitudinal studies. Hechtman L. Do They Grow Out of It? Long-term Outcomes of Childhood Disorders. 1996;1-16 American Psychiatric Press, Washington, DC.
36. Weiss G, Hechtman LT (1993): Hyperactive children grown up: ADHD in children, adolescents, and adults, New York: Guilford Press.
37. Wender P.H., Reimherr F.W. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 147:1990;1018-1020.
38. Wender P.H., Reimherr F.W., Wood D., Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry. 142:1985;547-552.
39. Wilens T.E. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 9:2000;573-603.
40. Wilens T.E., Biederman J. The stimulants. Psychiatr Clin North Am. 15:1992;191-222.
41. Wilens T.E., Biederman J., Prince J., Spencer T.J., Faraone S.V., Warburton R., et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 153:1996;1147-1153.
42. Wilens T.E., Spencer T.J., Biederman J., Girard K., Doyle R., Prince J., et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 158:2001;282-288.